This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks Hit 52-Week Highs

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


Oppenheimer analysts said that Radware could be negotiating a licensing agreement with Juniper Networks (JNPR).

"Based on our checks we believe Radware is in advanced negotiations with Juniper for a software licensing deal," Oppenheimer analysts wrote in a report Tuesday. "In our opinion, Juniper is looking to license Radware's ADC engine and integrate it with its own data center switch architecture, the QFabric. While details are still limited, we believe the deal could be substantial in size (~$70M- $100M) and over a long time frame (3-5 years). We note that Juniper and Radware have already announced a relationship in 4Q11 to sell Radware's ADC solution on Juniper's MX routers targeting the service provider market. Should the transaction materialize, we see ~$0.75 in EPS upside per annum for Radware at the midpoint of our estimates. Maintain Outperform."

Shares of Radware hit a 52-week high Wednesday of $40.83. The stock's 52-week low of $18.98 was set on Oct. 3.

Radware's forward P/E is 19.66; the average for telecommunications equipment companies is 11.16.

All four of the analysts who cover Radware rated it buy.

The stock has risen 34.05% year to date.

BioMarin Pharmaceutical

"BioMarin ended the quarter with total revenue of $116.2 million, inā€line enough with consensus of $118.8 million," Brean Murray Carret analysts wrote in an April 27 report. "Naglazyme revenue was $68 million, beating consensus of $60 million, primarily because of the Brazilian order that continues to be in the first quarter versus the fourth of the prior year. Kuvan sales were $32 million, which just beat consensus of $31 million. Aldurazyme worldwide net revenue was $45.9 million, with BioMarin only receiving $12 million, due to negative product transfer revenue of $6.4 million that will reverse in 2H12. The 1Q12 diluted GAAP EPS was $(0.21), which missed consensus of $(0.15), primarily due to higher than expected R&D expenses of $73.8 million, which was mainly due to GALNS manufacturing expenses and additional patients in the GALNS trial, all of which reflects physician optimism for the trial. The company ended 1Q12 with $288 million in cash and investments."

Shares of BioMarin hit a 52-week high on Wednesday of $39.20. The stock's 52-week low of $23.74 was set on Aug. 8.

Fourteen of the 18 analysts who cover BioMarin rated it buy; four analysts gave the stock a hold rating.

The stock has risen 11.98% year to date.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

-- Written by Alexandra Zendrian

>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to:

>To follow the writer on Twitter, go to Alexandra Zendrian.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMRN $64.26 -0.74%
CHDN $126.22 0.38%
LL $12.00 -2.80%
MTH $28.98 -2.10%
RDWR $10.38 -2.00%


Chart of I:DJI
DOW 15,930.97 -96.08 -0.60%
S&P 500 1,836.21 -17.23 -0.93%
NASDAQ 4,230.9480 -52.8050 -1.23%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs